Psychiatric Medications Beyond SSRIs and Fertility

The conversation about antidepressants and pregnancy has gotten significant attention. SSRIs are relatively well studied, and the guidance is increasingly clear. But millions of people take other psychiatric medications: mood stabilizers, antipsychotics, SNRIs, benzodiazepines, stimulants, and combinations of these. The fertility and pregnancy implications of these medications are less widely discussed and deserve the same careful attention.

Medication Classes and Reproductive Effects

Valproate: The Clearest Avoidance Case

Valproate (valproic acid, divalproex, Depakote) stands out as the psychiatric medication with the strongest evidence against use in pregnancy. It carries a major malformation rate of 9 to 11% and is associated with reduced cognitive scores in exposed children. The FDA has a boxed warning contraindicating its use during pregnancy for migraine prophylaxis and recommending it only when no alternative controls the condition.

Beyond teratogenicity, valproate can cause a PCOS-like syndrome in some women, with weight gain, insulin resistance, and menstrual irregularity that directly impair fertility. Women on valproate who are considering pregnancy should discuss alternatives with their prescriber well in advance.

Antipsychotics and Prolactin

Several antipsychotic medications raise prolactin by blocking dopamine receptors in the pituitary. Elevated prolactin suppresses GnRH pulsatility, which in turn suppresses LH and FSH, leading to anovulation, irregular periods, or amenorrhea.

The impact varies significantly by drug:

If you are on a prolactin-raising antipsychotic and experiencing menstrual irregularity, the first step is a prolactin level. If elevated, a conversation with your psychiatrist about switching to a prolactin-sparing alternative (quetiapine or aripiprazole) is worth exploring. The switch should prioritize psychiatric stability first and reproductive effects second.

Lithium in Pregnancy: Manageable with Monitoring

Lithium has a long-studied pregnancy profile. The primary concern is a small increase in the risk of Ebstein anomaly, a cardiac malformation, with first-trimester exposure. Earlier estimates put this risk very high, but more recent data suggests the absolute risk is roughly 1 in 1,000 exposed pregnancies (compared to 1 in 20,000 in the general population). This is meaningful but far lower than previously feared.

Lithium levels require close monitoring during pregnancy. Blood volume expansion dilutes levels, while declining renal clearance near delivery can cause toxic spikes. Most lithium prescribers check levels monthly during pregnancy and weekly near term.

SNRIs and the Neonatal Adaptation Period

SNRIs (venlafaxine, duloxetine) do not appear to cause major malformations. The primary concern is neonatal adaptation syndrome: a cluster of symptoms in the newborn (jitteriness, poor feeding, respiratory distress) that occurs in roughly 15 to 30% of exposed infants and typically resolves within days to two weeks.

Tapering or discontinuing before delivery to avoid neonatal symptoms is sometimes attempted, but this must be weighed against the risk of maternal relapse in the immediate postpartum period, which is itself a high-risk window for mood disorders.

The Role of Reproductive Psychiatry

Reproductive psychiatry is a growing subspecialty focused on mental health across the reproductive life cycle. A reproductive psychiatrist can help navigate medication choices, weigh individual risk factors, and serve as a bridge between your psychiatric care and your fertility or obstetric team.

If a reproductive psychiatrist is not available locally, many offer telehealth consultations. The Massachusetts General Hospital Center for Women's Mental Health and the Mothertobaby service both maintain resources and databases on medication safety in pregnancy.